These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26169860)

  • 21. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?
    Machado MV; Cortez-Pinto H
    Liver Int; 2014 Oct; 34(9):1291-4. PubMed ID: 24766162
    [No Abstract]   [Full Text] [Related]  

  • 24. The NASH drug dash.
    Chi KR
    Nat Rev Drug Discov; 2015 Jul; 14(7):447-8. PubMed ID: 26129791
    [No Abstract]   [Full Text] [Related]  

  • 25. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: another leap forward.
    Abdelmalek MF
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):85-86. PubMed ID: 33420415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Sanyal AJ
    Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
    Mintziori G; Polyzos SA
    Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
    Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G;
    Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug development: Sprint finish.
    Drew L
    Nature; 2017 Nov; 551(7681):. PubMed ID: 29168826
    [No Abstract]   [Full Text] [Related]  

  • 33. FXR agonists for NASH: How are they different and what difference do they make?
    Kremoser C
    J Hepatol; 2021 Jul; 75(1):12-15. PubMed ID: 33985820
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.
    Dash A; Figler RA; Blackman BR; Marukian S; Collado MS; Lawson MJ; Hoang SA; Mackey AJ; Manka D; Cole BK; Feaver RE; Sanyal AJ; Wamhoff BR
    Toxicol In Vitro; 2017 Mar; 39():93-103. PubMed ID: 27939613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of non-alcoholic fatty liver disease.
    Lisboa QC; Costa SM; Couto CA
    Rev Assoc Med Bras (1992); 2016 Dec; 62(9):872-878. PubMed ID: 28001263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
    Alawad AS; Levy C
    Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.
    Dajani A; AbuHammour A
    Saudi J Gastroenterol; 2016; 22(2):91-105. PubMed ID: 26997214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?
    Karpen SJ
    Gastroenterology; 2013 Sep; 145(3):508-10. PubMed ID: 23891611
    [No Abstract]   [Full Text] [Related]  

  • 40. Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.
    Mazzini GS; Khoraki J; Browning MG; Campos GM
    Cell Death Dis; 2018 Mar; 9(3):354. PubMed ID: 29500352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.